SBIR/STTR Research Award

Infection-Resistant Prosthetic Valve Sewing Cuffs

Award identifier 594cb1ce40e40134521971880e1dee187278ef86847f142f9949f30a5afbf8f3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$0

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOMOD SURFACES
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant):Cardiac valve replacement using prosthetic valves is indicated when progression of degenerative disease, annular dilatation or bacterial infection of the native valve results in valvular dysfunction. Bacterial infection is a major complication associated with implantation of these prosthetic valves. Infections are localized to the biomaterial/tissue interface leading to cuff and annular abscess formation. In phase I, an infection-resistant knitted polyester (Dacron) cuff material was developed in vitro with optimum antimicrobial properties via thermofixation (pad/heat) dyeing of the antibiotic ciprofloxacin (Cipro). Application of this technology resulted in slow, sustained antibiotic release without the use of exogenous binders. The goal of this phase II project is to assess this novel infection-resistant knitted Dacron cuff material in vivo. Our hypothesis is that application of quinolone antibiotics such as Cipro to Dacron sewing cuffs using our proprietary dyeing technology will significantly reduce cardiac valve infections when challenged with a significant bacterial inoculum. The specific aims of this phase II proposal are to: 1) apply Cipro to clinically-utilized sewing cuffs using technology developed in phase I, 2) evaluate antimicrobial activity of Cipro-dyed sewing cuffs via zone of inhibition, 3) examine physical properties of Cipro-dyed Dacron sewing cuffs, 4) implant unmodified (clinical standard) and Cipro-dyed sewing cuffs in a porcine heart valve infection model, 5) assess control and Cipro-dyed Dacron sewing cuffs via histological/microbiological techniques and 6) determine physical properties of Cipro-dyed sewing cuffs post-explantation. This technology, if successful, will be become the standard of care in the treatment of all forms of prosthetic endocarditis and may have an annual market in excess of $25 million. This technology can be applied to other medical devices that are comprised of Dacron such as vascular grafts, carotid patch material, wound dressings and suture material. This technology may also have broad application in other industries requiring biomaterials with antimicrobial properties such as respirators, facemasks, veterinary medicine and other commercial ventures.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.